Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis

• Published in: JAMA internal medicine Vol. 176; no. 4; p. 453
• Main Authors: Jaspers, Loes, Feys, Frederik, Bramer, Wichor M, Franco, Oscar H, Leusink, Peter, Laan, Ellen T M
• Format: Journal Article
• Language: English
• Published: United States 01.04.2016
• Subjects: Benzimidazoles - therapeutic use; Dizziness - chemically induced; Fatigue - chemically induced; Female; Humans; Libido; Nausea - chemically induced; Patient Satisfaction; Premenopause; Sexual Dysfunctions, Psychological - drug therapy; Treatment Outcome

In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, despite concern about suboptimal risk-benefit trade-offs. To conduct a systematic review and meta-analysis of randomized clinical trials...